Butterfly Embedded: A Semiconductor Pivot Catches Fire
Midjourney-fueled revenue surge and record margins mark a turning point as the company expands beyond handheld ultrasound.
BFLY · Earnings Call · 2026-07-30
A Pivot Beyond Handhelds
For most of its public life, Butterfly Network has been a story about democratizing handheld ultrasound. But the second-quarter 2026 earnings call signaled a decisive shift: the company is now an Ultrasound-on-Chip platform with an Embedded partnership business that is suddenly contributing outsized growth. The numbers tell part of the story: total revenue hit a record $32.6M, up 39% year-over-year, while Embedded revenue surged 439% to $10.8M. The stock has responded dramatically, with a +132% return over the past 90 days, though it remains far below its 2021 highs. The strategic pivot is unmistakable. CEO Joseph DeVivo, who spent years describing Butterfly as a point-of-care ultrasound company, now frames the Embedded platform as the real prize. "We can finally unpack what a couple of our partners have discovered is possible with our technology" “.” — Joseph DeVivo, Chief Executive Officer · 2026-07-30 That unpacking centers on Midjourney's announcement of a whole-body scanner built around Butterfly's chip — a validation that turned the market's head. The Embedded business is no longer a side project. With 11 partners and new deals signed this quarter, including two more brain-computer interface and women's health wearables, the company is building a scalable, recurring-revenue model. When asked about the ceiling on partnerships, DeVivo replied, "I don't see in my mind at the moment a limit to the partnerships" “.” — Joseph DeVivo, Chief Executive Officer · 2026-07-30 This is a marked change from earlier quarters when Embedded was described as a small, experimental adjunct to the core hardware business.The Embedded Flywheel
The Midjourney announcement has acted as a gravitational pull for inbound interest. The $74M contract signed in late 2025, with its upfront payment, annual license fees, and milestone-based revenue, is now being recognized as work progresses. CFO John Doherty noted, "Second quarter revenue was a record $32.6 million, an increase of 39% year-over-year" “.” — John Doherty, Chief Financial Officer · 2026-07-30 But the bigger story is what this means for the company's identity. The financials confirm the strategic direction. The top-line jump was driven by Embedded, and gross margin expanded to a record 71% from 64% a year ago. The company is still unprofitable, but adjusted EBITDA loss narrowed to $1.4M, a 78% improvement. This is a company that is monetizing its chip architecture rather than just selling $2,000 probes. In prior quarters, management had teased the potential of Embedded. In February 2026, DeVivo said, "we have, I think, now, eight or nine embedded partners today, and the pipeline is pretty large" “.” — Joseph M. DeVivo, Chief Executive Officer · 2026-02-26 Now, with 11 partners and two major public wins, that promise is materializing.Core POCUS and Home Care: Still the Anchor
It would be a mistake to read the Embedded pivot as an abandonment of the legacy business. Core POCUS revenue grew 2% to $21.9M, led by strong U.S. health system and medical school demand. The company's Compass AI software is becoming a strategic wedge, with six new enterprise deals this quarter and a pipeline that has grown five-fold since last year. The VCOM medical school partnership, worth over $10M in total contract value, is a template for future institutional sales. Home and Community Care is finally moving from pilot to commercialization. The first commercial state launches October 1, with 15-30 nurses to be trained. Revenue is expected to start in Q4 2026. This segment has been a long time coming. A year ago, DeVivo was more cautious, saying, "It will be done when it's done. I just don't control it" “.” — Joseph DeVivo, Chief Executive Officer · 2025-10-31 Now, the execution is on track, and management is discussing a fixed fee per patient plus per-scan charges, a model that could scale nationwide. The company's full-year guidance was raised to $119-123M, implying 22-26% growth over 2025. Adjusted EBITDA loss is expected to narrow to $19-23M. Importantly, the guidance includes incremental investments in R&D for the next-gen probe (P5.1, launching Q1 2027) and the Apollo chip, as well as the commercial rollout of Home Care.Why This Matters
Butterfly is no longer just a hardware maker; it is building a semiconductor platform that partners can license and embed in their own products. The Midjourney announcement was a proof point, and the pipeline of potential partners is expanding into fields as diverse as neurotechnology, robotics, and wearables. The company's 90-day stock surge (+132%) suggests the market is beginning to appreciate this optionality. Still, risks remain. The stock trades at just 1x price-to-revenue, and the company has a history of volatility. The Embedded business is still nascent, and much of the revenue is tied to a handful of partners. But the direction is clear. As DeVivo closed the call:That vision now extends far beyond the handheld. With a record quarter, a raised outlook, and a robust partner ecosystem, Butterfly is positioning itself as the silicon behind the future of ultrasound — and the market is starting to listen.Butterfly has had a vision of democratizing imaging, of having every doctor, every nurse with their own probe, and that vision has increased, and our execution is right on.